Organon & Co. (OGN)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$1,116.0M
Cash & Equivalents
$225.0M
Quarterly Burn Rate
$3,550M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (17 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
CARBIDOPA, LEVODOPA
SINEMET |
APPROVED | Acute Coronary Syndrome, Acute Gout, Acute Migraine, Acute Migraine With or Without Aura in Adolescents, Acute Pain Following a Total Abdominal Hysterectomy, Acute Rhinosinusitis, Adenocarcinoma, Adenoidectomy, Adenoids, Adenoids Hypertrophy, Airway Inflammation, Allergic Airway Disease, Allergic Rhinitis, Allergies, Androgenetic Alopecia, Ankylosing Spondylitis, Anovulation, Aortic Stenosis, Arthritis, Arthritis, Rheumatoid, Asthma, Asthma, Bronchial, Asthma, Exercise-Induced, Atherosclerosis, Atherosclerotic Cardiovascular Disease, Atherosclerotic Disease, Atopic Dermatitis, Atopy, Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia (BPH), Bipolar 1 Disorder, Bipolar Disorder, Bipolar Disorder, Pediatric, Bipolar I Disorder, Bone Neoplasms, Breast Cancer, Bronchiolitis, Cancer, Cardiovascular Diseases, Cardiovascular Disorder, Cholesterol, Chronic Asthma, Chronic Idiopathic Urticaria, Chronic Low Back Pain, Chronic Obstructive Pulmonary Disease (COPD), Climacteric Symptoms, Conjunctivitis, Allergic, |
|
HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM
HYZAAR |
APPROVED | — |
|
EZETIMIBE, SIMVASTATIN
VYTORIN |
APPROVED | — |
|
MIRTAZAPINE
REMERON |
APPROVED | — |
|
BETAMETHASONE ACETATE, BETAMETHASONE SODIUM PHOSPHATE
CELESTONE SOLUSPAN |
APPROVED | — |
|
MONTELUKAST SODIUM
SINGULAIR |
APPROVED | — |
|
EZETIMIBE
ZETIA |
APPROVED | — |
|
FINASTERIDE
PROPECIA |
APPROVED | — |
|
DESLORATADINE
CLARINEX |
APPROVED | — |
|
BETAMETHASONE DIPROPIONATE, CLOTRIMAZOLE
LOTRISONE |
NDA | — |
|
SIMVASTATIN
ZOCOR |
NDA | — |
|
DESLORATADINE, PSEUDOEPHEDRINE SULFATE
CLARINEX D 24 HOUR |
NDA | — |
|
ETONOGESTREL
NEXPLANON |
NDA | — |
|
ATORVASTATIN CALCIUM, EZETIMIBE
LIPTRUZET |
NDA | — |
|
BETAMETHASONE DIPROPIONATE
DIPROLENE |
NDA | — |
|
MOMETASONE FUROATE
ELOCON |
NDA | — |
|
ALENDRONATE SODIUM
FOSAMAX |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase3 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05172726 | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | PHASE3 | Active Not Recruiting | 58 |
| NCT07265479 | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atop... | PHASE3 | Recruiting | 180 |
| NCT06561321 | Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma | PHASE2 | Active Not Recruiting | 6 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.